The use of a combination of tramadol and paracetamol in the treatment of pain. A clinical case report Case report
Article Sidebar
Main Article Content
Abstract
This article discusses the importance of multimodal pharmacotherapy in pain management, with particular emphasis on the combination of paracetamol and tramadol, which relies on the synergistic action of distinct analgesic mechanisms. The mechanisms of action of both drugs, their pharmacokinetic profile, safety, and potential interactions are presented, emphasizing the potential for effective analgesia at lower doses and with a lower risk of adverse effects than with monotherapy. This case report of a 72-year-old female patient with chronic pain due to osteoarthritis and osteoporosis illustrates the complexity of pain management in a patient with multimorbidity and functional limitations. The use of tramadol + paracetamol combination therapy in a multimodal model, along with interventional methods and rehabilitation, has limited efficacy in addressing sleep disorders and quality with adequate treatment. The discussion highlights the general spectrum of indications for this combination, including receptor-mediated, neuropathic, and mixed problems, as well as the principles of individualization and dose titration. The article emphasizes that exercise therapy requires a comprehensive, integrated, and regularly monitored registered physician.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023; 31(4): 458-66. https://doi.org/10.1016/j.joca.2022.11.005.
3. Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014; 71(1): 11-23.
4. Hoshijima H, Hunt M, Nagasaka H et al. Systematic Review of Systemic and Neuraxial Effects of Acetaminophen in Preclinical Models of Nociceptive Processing. J Pain Res. 2021; 14: 3521-52. https://doi.org/10.2147/JPR.S308028.
5. Barrière DA, Boumezbeur F, Dalmann R et al. Paracetamol is a centrally acting analgesic using mechanisms located in the periaqueductal grey. Br J Pharmacol. 2020; 177: 1773-92. https://doi.org/10.1111/bph.14934.
6. Stampf JL, Ciotu CI, Heber S et al. Analgesic Action of Acetaminophen via Kv7 Channels. Int J Mol Sci. 2022; 24(1): 650. https://doi.org/10.3390/ijms24010650.
7. Hodgman MJ, Garrard AR. A review of acetaminophen poisoning. Crit Care Clin. 2012; 28(4): 499-516. https://doi.org/10.1016/j.ccc.2012.07.006.
8. Mallet C, Desmeules J, Pegahi R et al. An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact. J Pain Res. 2023; 16: 1081-94. https://doi.org/10.2147/JPR.S393809.
9. Charakterystyka Produktu Leczniczego. Paracetamol.
10. Schug SA, Palmer GM, Scott DA et al.; APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence (5th edition). ANZCA & FPM, Melbourne 2020.
11. Pickering G, Kotlińska-Lemieszek A, Krcevski Skvarc N et al. Pharmacological Pain Treatment in Older Persons. Drugs Aging. 2024; 41(12): 959-76. https://doi.org/10.1007/s40266-024-01151-8.
12. Bravo L, Mico JA, Berrocoso E. Discovery and development of tramadol for the treatment of pain. Expert Opin Drug Discov. 2017; 12(12): 1281-91. https://doi.org/10.1080/17460441.2017.1377697.
13. Barakat A. Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019; 33(5): 481-501. https://doi.org/10.1007/s40263-019-00623-5.
14. Long T, Cristofoletti R, Cicali B et al. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition. J Clin Pharmacol. 2022; 62(1): 76-86. https://doi.org/10.1002/jcph.1951.
15. Kocot-Kępska M. Połączenie paracetamolu i tramadolu – fakty i mity. Medycyna Faktów. 2024; 4(65): 516-22. https://doi.org/10.24292/01.MF.0424.13.
16. Australian Public Assessment Report for Tramadol hydrochloride. Paracetamol Proprietary Product Name: Zaldiar.
17. Cao Z, Han K, Lu H et al. Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses. Drugs. 2024; 84(8): 953-67. https://doi.org/10.1007/s40265-024-02065-w.
18. Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017; 5(5): CD012508. https://doi.org/10.1002/14651858.CD012508.pub2.
19. Chaparro LE, Wiffen PJ, Moore RA et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; 2012(7): CD008943. https://doi.org/10.1002/14651858.CD008943.pub2.
20. Lee EY, Lee EB, Park BJ et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial. Clin Ther. 2006; 28(12): 2052-60. https://doi.org/10.1016/j.clinthera.2006.12.019.
21. Stępień A, Kozubski W, Rożniecki J et al. Leczenie migreny. Zalecenia opracowane przez grupę ekspertów Polskiego Towarzystwa Bólów Głowy, Polskiego Towarzystwa Badania Bólu i Sekcji Badania Bólu Polskiego Towarzystwa Neurologicznego. BÓL. 2020; 21(2): 11-30. https://doi.org/10.5604/01.3001.0014.4591.